Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 7/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 7/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KIF11 | P52732 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054571 | 0.88 | KIF11 (0.47) | KDM4EKIF11MAPTGRIA1KCNH2 | |
| SCHEMBL21022847 | 0.79 | KIF11 (0.47) | KIF11MAPTHSD17B10KCNH2SCN10A | |
| SCHEMBL29580921 | 0.79 | KDM4E (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL440536 | 0.79 | KDM4E (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21022846 | 0.79 | HPGD (0.50) | KDM4EKIF11MAPTHSD17B10KCNH2 | |
| SCHEMBL14355034 | 0.77 | KIF11 (0.59) | KDM4EKIF11MEN1KMT2A | |
| SCHEMBL11269962 | 0.76 | KDM4E (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6418643 | 0.75 | MAPT (0.75) | KDM4EMAPTTP53MEN1LMNA | |
| SCHEMBL25243502 | 0.73 | KIF11 (0.65) | KDM4EKIF11MEN1ALDH1A1LMNA | |
| SCHEMBL31369133 | 0.73 | KIF11 (0.65) | KDM4EKIF11MAPTKCNH2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20160340314-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440951-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150239865-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9067887-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-7842708-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7626039-B2 | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239865-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | GRIN2D 3985/4885GRIN3B 4283/4885GRIN1 3929/4885 |
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | GRIN2D 3985/4885GRIN3B 4283/4885GRIN1 3929/4885 |
| US-20160340314-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | GRIN2D 3985/4885GRIN3B 4283/4885GRIN1 3929/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | GRIN2D 4160/4885GRIN3B 4303/4885GRIN1 3870/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | GRIN2D 4093/4885GRIN3B 4279/4885GRIN1 4016/4885 |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | GRIN2D 4722/4885GRIN3B 4053/4885GRIN1 3942/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | GRIN2D 4053/4885GRIN3B 4315/4885GRIN1 3978/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | GRIN2D 3985/4885GRIN3B 4283/4885GRIN1 3929/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | GRIN2D 4123/4885GRIN3B 4437/4885GRIN1 4120/4885 |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | GRIN2D 4501/4885GRIN3B 3634/4885GRIN1 3721/4885 |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | GRIN2D 4160/4885GRIN3B 4303/4885GRIN1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.